• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于合并严重细胞因子血症 COVID-19 的囊性纤维化的 α-1 抗胰蛋白酶。

Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19.

机构信息

Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland.

Beaumont Hospital, Dublin, Ireland.

出版信息

J Cyst Fibros. 2021 Jan;20(1):31-35. doi: 10.1016/j.jcf.2020.11.012. Epub 2020 Nov 20.

DOI:10.1016/j.jcf.2020.11.012
PMID:33288475
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7678455/
Abstract

BACKGROUND

The clinical course of severe COVID-19 in cystic fibrosis (CF) is incompletely understood. We describe the use of alpha-1 antitrypsin (AAT) as a salvage therapy in a critically unwell patient with CF (PWCF) who developed COVID-19 while awaiting lung transplantation.

METHODS

IV AAT was administered at 120 mg/kg/week for 4 consecutive weeks. Levels of interleukin (IL)-1β, IL-6, IL-8, and soluble TNF receptor 1 (sTNFR1) were assessed at regular intervals in plasma, with IL-1β, IL-6, IL-8 and neutrophil elastase (NE) activity measured in airway secretions. Levels were compared to baseline and historic severe exacerbation measurements.

RESULTS

Systemic and airway inflammatory markers were increased compared to both prior exacerbation and baseline levels, in particular IL-6, IL-1β and NE activity. Following each AAT dose, rapid decreases in each inflammatory parameter were observed. These were matched by marked clinical and radiographic improvement.

CONCLUSIONS

The results support further investigation of AAT as a COVID-19 therapeutic, and re-exploration of its use in CF.

摘要

背景

囊性纤维化 (CF) 患者中严重 COVID-19 的临床病程尚不完全清楚。我们描述了在等待肺移植时患有 CF（PWCF）并发生 COVID-19 的情况下，使用α-1 抗胰蛋白酶 (AAT) 作为挽救疗法的情况。

方法

每周给予 IV AAT 120mg/kg，连续 4 周。定期评估血浆中白细胞介素 (IL)-1β、IL-6、IL-8 和可溶性 TNF 受体 1 (sTNFR1) 的水平，并测量气道分泌物中的 IL-1β、IL-6、IL-8 和中性粒细胞弹性蛋白酶 (NE) 活性。将这些水平与基线和既往严重加重的测量值进行比较。

结果

与既往加重和基线水平相比，全身和气道炎症标志物均升高，尤其是 IL-6、IL-1β 和 NE 活性。每次给予 AAT 后，观察到每个炎症参数迅速下降。这与明显的临床和影像学改善相匹配。

结论

结果支持进一步研究 AAT 作为 COVID-19 治疗药物，并重新探索其在 CF 中的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ae8/7678455/f3990d5c57ce/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ae8/7678455/7efdb2d8654a/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ae8/7678455/bb1413e8275b/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ae8/7678455/f3990d5c57ce/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ae8/7678455/7efdb2d8654a/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ae8/7678455/bb1413e8275b/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ae8/7678455/f3990d5c57ce/gr3_lrg.jpg

相似文献

1
Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19.用于合并严重细胞因子血症 COVID-19 的囊性纤维化的 α-1 抗胰蛋白酶。
J Cyst Fibros. 2021 Jan;20(1):31-35. doi: 10.1016/j.jcf.2020.11.012. Epub 2020 Nov 20.
2
A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19.一项关于静脉注射α-1抗胰蛋白酶治疗新型冠状病毒肺炎继发急性呼吸窘迫综合征的随机、双盲、安慰剂对照试验。
Med. 2022 Apr 8;3(4):233-248.e6. doi: 10.1016/j.medj.2022.03.001. Epub 2022 Mar 11.
3
A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.静脉注射血浆纯化的α-1 抗胰蛋白酶治疗 SARS-CoV-2 诱导的急性呼吸窘迫综合征的随机、双盲、安慰剂对照、初步临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 19;22(1):288. doi: 10.1186/s13063-021-05254-0.
4
Characterization of the Inflammatory Response to Severe COVID-19 Illness.严重 COVID-19 疾病炎症反应的特征。
Am J Respir Crit Care Med. 2020 Sep 15;202(6):812-821. doi: 10.1164/rccm.202005-1583OC.
5
Alpha-1 Antitrypsin Therapy in Cystic Fibrosis and the Lung Disease Associated with Alpha-1 Antitrypsin Deficiency.α1抗胰蛋白酶疗法在囊性纤维化及与α1抗胰蛋白酶缺乏相关的肺部疾病中的应用
Ann Am Thorac Soc. 2016 Apr;13 Suppl 2:S191-6. doi: 10.1513/AnnalsATS.201504-245KV.
6
Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.重组α1-抗胰蛋白酶疗法在囊性纤维化中的安全性和有效性。
Pediatr Pulmonol. 2006 Feb;41(2):177-83. doi: 10.1002/ppul.20345.
7
alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients.α1-抗胰蛋白酶吸入可减轻囊性纤维化患者的气道炎症。
Eur Respir J. 2007 Feb;29(2):240-50. doi: 10.1183/09031936.00047306. Epub 2006 Oct 18.
8
A novel neutrophil derived inflammatory biomarker of pulmonary exacerbation in cystic fibrosis.一种新型中性粒细胞衍生的炎症生物标志物，可用于预测囊性纤维化肺部恶化。
J Cyst Fibros. 2012 Mar;11(2):100-7. doi: 10.1016/j.jcf.2011.09.010. Epub 2011 Oct 28.
9
Human neutrophil elastase and elastase/alpha 1-antiprotease complex in cystic fibrosis. Comparison with interstitial lung disease and evaluation of the effect of intravenously administered antibiotic therapy.囊性纤维化中的人中性粒细胞弹性蛋白酶和弹性蛋白酶/α1-抗蛋白酶复合物。与间质性肺病的比较及静脉注射抗生素治疗效果的评估。
Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):580-5. doi: 10.1164/ajrccm/144.3_Pt_1.580.
10
Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications.SARS-CoV-2 相关急性呼吸窘迫综合征中蛋白酶-抗蛋白酶的区室化：治疗意义。
EBioMedicine. 2022 Mar;77:103894. doi: 10.1016/j.ebiom.2022.103894. Epub 2022 Feb 22.

引用本文的文献

1
Identification of Anoikis-Related Genes in Driving Immune-Inflammatory Responses in Ulcerative Colitis Based on Bioinformatics Analysis and Machine Learning.基于生物信息学分析和机器学习鉴定溃疡性结肠炎中驱动免疫炎症反应的失巢凋亡相关基因
J Inflamm Res. 2025 Mar 5;18:3227-3242. doi: 10.2147/JIR.S509659. eCollection 2025.
2
Neutrophil proteases are protective against SARS-CoV-2 by degrading the spike protein and dampening virus-mediated inflammation.中性粒细胞蛋白酶通过降解刺突蛋白和抑制病毒介导的炎症反应对 SARS-CoV-2 具有保护作用。
JCI Insight. 2024 Apr 8;9(7):e174133. doi: 10.1172/jci.insight.174133.
3
Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity.

本文引用的文献

1
Characterization of the Inflammatory Response to Severe COVID-19 Illness.严重 COVID-19 疾病炎症反应的特征。
Am J Respir Crit Care Med. 2020 Sep 15;202(6):812-821. doi: 10.1164/rccm.202005-1583OC.
2
A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis.一份多国报告，旨在描述囊性纤维化患者中 SARS-CoV-2 感染的特征。
J Cyst Fibros. 2020 May;19(3):355-358. doi: 10.1016/j.jcf.2020.04.012. Epub 2020 Apr 25.
3
Improved Prognosis in Cystic Fibrosis: Consideration for Intensive Care during the COVID-19 Pandemic.
囊性纤维化跨膜电导调节因子可能影响 SARS-CoV-2 感染和 COVID-19 疾病严重程度的机制。
FASEB J. 2023 Nov;37(11):e23220. doi: 10.1096/fj.202300077R.
4
Alpha-1-antitrypsin antagonizes COVID-19: a review of the epidemiology, molecular mechanisms, and clinical evidence.α-1-抗胰蛋白酶拮抗 COVID-19：流行病学、分子机制和临床证据综述。
Biochem Soc Trans. 2023 Jun 28;51(3):1361-1375. doi: 10.1042/BST20230078.
5
Diagnosis and Management of Cystic Fibrosis Exacerbations.囊性纤维化加重的诊断和管理。
Semin Respir Crit Care Med. 2023 Apr;44(2):225-241. doi: 10.1055/s-0042-1760250. Epub 2023 Feb 6.
6
Genetic and Serum Screening for Alpha-1-Antitrypsin Deficiency in Adult Patients with Cystic Fibrosis: A Single-Center Experience.成年囊性纤维化患者α-1抗胰蛋白酶缺乏症的基因与血清筛查：单中心经验
Biomedicines. 2022 Dec 14;10(12):3248. doi: 10.3390/biomedicines10123248.
7
A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19.一项关于静脉注射α-1抗胰蛋白酶治疗新型冠状病毒肺炎继发急性呼吸窘迫综合征的随机、双盲、安慰剂对照试验。
Med. 2022 Apr 8;3(4):233-248.e6. doi: 10.1016/j.medj.2022.03.001. Epub 2022 Mar 11.
8
A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application.α1-抗胰蛋白酶结合蛋白的免疫调节作用及潜在治疗应用研究进展
Int J Mol Sci. 2022 Feb 23;23(5):2441. doi: 10.3390/ijms23052441.
9
The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment.跨膜蛋白酶 TMPRSS2 作为 COVID-19 治疗的治疗靶点。
Int J Mol Sci. 2022 Jan 25;23(3):1351. doi: 10.3390/ijms23031351.
10
Hindrance of the Proteolytic Activity of Neutrophil-Derived Serine Proteases by Serine Protease Inhibitors as a Management of Cardiovascular Diseases and Chronic Inflammation.丝氨酸蛋白酶抑制剂对中性粒细胞衍生丝氨酸蛋白酶蛋白水解活性的阻碍作用在心血管疾病和慢性炎症管理中的应用
Front Chem. 2021 Nov 15;9:784003. doi: 10.3389/fchem.2021.784003. eCollection 2021.
囊性纤维化患者预后的改善：COVID-19大流行期间重症监护的考量
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1434-1435. doi: 10.1164/rccm.202004-0999LE.
4
Consequences of Abrupt Cessation of Alpha-Antitrypsin Replacement Therapy.α-抗胰蛋白酶替代疗法突然中断的后果。
N Engl J Med. 2020 Apr 9;382(15):1478-1480. doi: 10.1056/NEJMc1915484.
5
Alpha-Antitrypsin Deficiency.α-抗胰蛋白酶缺乏症
N Engl J Med. 2020 Apr 9;382(15):1443-1455. doi: 10.1056/NEJMra1910234.
6
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.中国武汉 2019 年冠状病毒病肺炎患者急性呼吸窘迫综合征和死亡的相关危险因素。
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
7
Impaired Airway Epithelial Barrier Integrity in Response to Proteases, Novel Insights Using Cystic Fibrosis Bronchial Epithelial Cell Secretomics.蛋白酶作用下气道上皮屏障完整性受损：囊性纤维化支气管上皮细胞分泌组学的新见解。
Front Immunol. 2020 Feb 25;11:198. doi: 10.3389/fimmu.2020.00198. eCollection 2020.
8
Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease.囊性纤维化基金会关于晚期囊性纤维化肺病患者治疗的共识指南。
J Cyst Fibros. 2020 May;19(3):344-354. doi: 10.1016/j.jcf.2020.02.015. Epub 2020 Feb 27.
9
Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis.NLRP3 炎性小体特异性抑制作为囊性纤维化抗炎策略。
Am J Respir Crit Care Med. 2019 Dec 1;200(11):1381-1391. doi: 10.1164/rccm.201905-1013OC.
10
The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial.双剂量 α1-抗胰蛋白酶增强疗法的生物学效应。一项初步临床试验。
Am J Respir Crit Care Med. 2019 Aug 1;200(3):318-326. doi: 10.1164/rccm.201901-0010OC.